These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12928808)

  • 1. [Suspected cases of severe side effects after infliximab (Remicade) in Germany].
    Andus T; Stange EF; Höffler D; Keller-Stanislawski B
    Med Klin (Munich); 2003 Aug; 98(8):429-36. PubMed ID: 12928808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Suspected cases of severe side effects after infliximab (Remicade) in Germany].
    Thürmann PA
    Med Klin (Munich); 2003 Aug; 98(8):428. PubMed ID: 12928807
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
    Bondeson J; Maini RN
    Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label uses and side effects of infliximab.
    Scheinfeld N
    J Drugs Dermatol; 2004; 3(3):273-84. PubMed ID: 15176162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for the prevention and management of tuberculosis in patients taking infliximab.
    Salmon-Ceron D; ;
    Ann Med Interne (Paris); 2002 Nov; 153(7):429-31. PubMed ID: 12598827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.
    Levälampi T; Korpela M; Vuolteenaho K; Moilanen E
    Scand J Rheumatol; 2008; 37(1):6-12. PubMed ID: 18189188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
    Katz JA; Antoni C; Keenan GF; Smith DE; Jacobs SJ; Lichtenstein GR
    Am J Gastroenterol; 2004 Dec; 99(12):2385-92. PubMed ID: 15571587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of infliximab in the course of treatment of Crohn's disease.
    Bratcher JM; Korelitz BI
    Expert Opin Drug Saf; 2006 Jan; 5(1):9-16. PubMed ID: 16370952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
    Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF antibody in Crohn's disease--status of information, comments and recommendations of an international working group.
    Lochs H; Adler G; Beglinger C; Duchmann R; Emmrich J; Ewe K; Gangl A; Gasché C; Hahn E; Hoffmann P; Kaskas B; Malchow H; Pohl C; Raedler A; Renner E; Schölmerich J; Schreiber S; Stange E; Tilg H; Vogelsang H; Weigert N; Zeitz M
    Z Gastroenterol; 1999 Jun; 37(6):509-12. PubMed ID: 10427657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
    Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
    Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Remicade in therapy of rheumatoid arthritis and Crohn diseases--no reason for panic].
    Kalden JR; Lochs H; Wollheim H
    Z Rheumatol; 2002 Aug; 61(4):466-8. PubMed ID: 12426854
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.